Product Description: RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors[1][2][3].
Applications: Cancer-programmed cell death
Formula: C19H24N6O3
References: [1]Laurie B. Schenkel, et al. Heterobicyclic amides as inhibitors of cd38. WO2021021986A1./[2]Shambharkar, et al. Small molecule inhibitor of CD38 modulates its intra-and extracellular functions leading to antitumor activity. Cancer Research 81.13_Supplement (2021): 1344-1344./[3]Huang Y, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024 Feb 20;5(2):101400.
CAS Number: 2597933-17-8
Molecular Weight: 384.43
Compound Purity: 98.87
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: CD38;LAG-3;PD-1/PD-L1;Tim3
English
Deutsch
